As the Oregon PDAB reviews its drug review process, the EACH Coalition submitted comments to the board outlining concerns with drug reviews and outlining ways to improve the process and protect patients.
The letter applauded the Oregon PDAB’s decision to halt drug reviews for 2024 and focus efforts on improving the process in 2025. The letter emphasized the importance of protecting patient access to medications and ensuring patient voices and perspectives are a critical part of the process.